Bruce Strober, Laura Ferris, Kristina Callis Duffin, Jud C Janak, Adam P Sima, Thomas Eckmann, Manish Patel, Huzefa Photowala, Vishvas Garg, April Armstrong
BACKGROUND: Psoriasis, an inflammatory skin disease, is often treated with biologic therapeutics. OBJECTIVE: To determine the real-world treatment effectiveness of risankizumab, an IL-23 inhibitor, in the treatment of moderate-to-severe plaque psoriasis. METHODS: A retrospective, observational study was conducted using the CorEvitas Psoriasis Registry for eligible adults with a diagnosis of moderate-to-severe psoriasis and persistent use of risankizumab at 12 (±3) months after initiation...
September 20, 2023: Journal of the American Academy of Dermatology